Usually not for the ketamine itself. Most US health plans treat ketamine for depression as off-label use, and many class it as experimental: Aetna’s policy on ketamine, last reviewed in December 2025, lists depression among the uses it considers experimental, investigational or unproven, by all five routes it lists, from infusion to tablet. That label is a rule about paying for a drug outside its licensed use, not a verdict on whether ketamine suits you, which is a question for a doctor at assessment. What plans pay for more often is the care around the ketamine: the psychiatric visits and the therapy.
This page covers US health insurance first; how payment works in the UK and the EU is set out further down.
| Part of a ketamine course | How often US plans pay | Why |
|---|---|---|
| Psychiatric assessment and follow-up visits | Often, under the mental health benefit | Behavioral health treatment is an essential benefit of Marketplace plans |
| Psychotherapy, including integration sessions | Often, when billed as psychotherapy | Same benefit |
| Intravenous ketamine infusion | Rarely: a few plans, with prior approval and strict criteria | Off-label for depression, classed as experimental by many insurers |
| Ketamine by mouth, lozenge, nasal spray or injection | Almost never | Listed as investigational or experimental in the policies below |
| Ketamine-assisted therapy sold as one package | Almost never | Aetna classes it as experimental for depression |
| A residential programme abroad, ours included | Not claimed: paid directly | One sum, quoted in writing on the introductory call |
If a doctor has suggested ketamine and you want to know whether it suits your history before you spend weeks on a claim, you can refer yourself for an assessment without a referral from your own doctor.
What insurance usually covers
Most plans pay for the psychiatric care and therapy around a ketamine course far more readily than for the ketamine session. For Marketplace plans that is written into the rules: HealthCare.gov lists behavioral health treatment, such as psychotherapy and counselling, as an essential health benefit every Marketplace plan must include, and parity rules stop a plan from limiting it more tightly than medical and surgical care. If your cover comes from an employer, that page is not about your plan: the behavioral health section of your own policy wording is what decides.
Ketamine is approved by the FDA as an anaesthetic, and in an October 2023 alert about ketamine compounded by pharmacies the FDA stated that ketamine is not FDA approved for the treatment of any psychiatric disorder. Insurers write their own medical policies on off-label use. Aetna’s Clinical Policy Bulletin 0938 classes ketamine for depression, by every route it lists, and ketamine-assisted therapy with it, as experimental, investigational or unproven.
A few plans go further: a 2022 policy from Blue Cross and Blue Shield of Vermont covered intravenous infusions for treatment-resistant depression under a long list of conditions, and classed every other route as investigational. Its criteria are below. That split is why people on r/KetamineTherapy describe both outcomes: “infusions aren’t covered by insurance” in one thread, and a plan that “covered infusions” until it dropped them in another.
Which kind of plan you have is in its written policy on ketamine. Ask the insurer four things:
- whether the plan has a written policy on ketamine, and for a copy of it by name
- which billing codes for a ketamine session it covers, if any
- whether prior authorisation is needed, and for which route
- what counts as off-label or experimental under your own policy
Check the answers against your own policy wording, then give them to the doctor who would prescribe: the prior authorisation request is built from these points.
Ketamine is not a first-line treatment for depression, and it is not the last resort it is sometimes described as either.
The usual sequence starts with psychotherapy, an antidepressant or both, then a change of drug or an added medication if the first does not work. When two antidepressants at a proper dose, taken long enough to judge, have failed in the same episode, the depression is described as treatment-resistant.
Most of the research was done in this group, and it is the main indication for esketamine, the licensed nasal-spray form. In the EU, esketamine is also licensed for short-term use in a depressive psychiatric emergency. Ketamine given by infusion is not licensed for depression at all: it is prescribed off-label, on the treating doctor’s clinical judgement and responsibility. That judgement can extend to people who have not tried two antidepressants, but the evidence there is thinner, and patients should be told so. What does not change with the setting is the requirement for a proper psychiatric assessment first.
At that point the realistic choices are another antidepressant or an augmentation strategy, ketamine, repetitive transcranial magnetic stimulation, electroconvulsive therapy, and for some people an intensive or residential programme instead of weekly outpatient care.
These options do not sit on one scale. Electroconvulsive therapy has the strongest evidence in severe depression and the heaviest burden. Transcranial magnetic stimulation is non-invasive with a lighter side-effect profile and a slower course. Ketamine acts fastest and does not hold on its own without a plan for what comes after.
What counts as a proper dose taken long enough is worth pinning down, because mislabelling here is the most common reason someone gets called treatment-resistant when they are not. It means a therapeutic dose, taken consistently, generally for several weeks at target dose.
Someone who stopped an antidepressant early because of side effects, or never reached a therapeutic dose, has a different problem with a different answer, and should say so during assessment.
Checked for medical accuracy by Dr Christopher Gauci, MD MRCS(Ed) EDAIC on 1 October 2026. The check covers this section. Everything else on the page is written by our editorial team and verified against primary sources.
Why a covered drug does not mean a covered procedure
An insurer pays for each line separately, and a ketamine session is several lines: the drug, the act of giving it, the monitoring visit and any therapy. Each line is checked against the diagnosis on the claim. Ketamine is a familiar drug to a plan, because it is approved and used as an anaesthetic. That coverage belongs to its approved use.
Depression sits outside that approved use, and that off-label status is what an insurer checks the claim against.
Aetna’s policy shows how the pairing works. It names the codes for giving an infusion (CPT 96365 to 96368) and an injection (96372), notes that ketamine and ketamine-assisted therapy have no specific billing code of their own, and lists the major depressive disorder diagnoses, ICD-10 F32.0 to F33.9, among those not covered for these uses. An infusion code next to a depression diagnosis is the combination that gets refused.
The pharmacy side follows the same logic. Ketamine sold for home use, such as lozenges, is often compounded, and the same FDA alert notes that compounded drugs have no FDA-approved indications of their own. The Vermont policy, for its part, required infusions to go through the medical benefit, not the pharmacy one.
So a clinic that says it takes insurance may mean it bills the visit and the therapy, while the infusion line stays with you. Ask the clinic for the codes it will bill before the first session, and ask your plan about each one. What happens during an infusion for depression is set out separately.
What your doctor needs to send for approval: documents, diagnosis wording, medication history
Where a plan covers ketamine at all, it does so through prior authorisation: your doctor asks the plan before treatment, with documents showing that you meet its written criteria. The 2022 Vermont policy is a useful example because it is specific. It asked for:
- a diagnosis of major depressive disorder, unipolar and treatment-resistant
- a severity score from a standard rating scale: 17 or more on the HAM-D, or 28 or more on the MADRS, both scales a clinician fills in during an interview
- no response to at least four FDA-approved antidepressants from at least two drug classes, each taken at a therapeutic dose for at least six weeks, plus at least two trials of an added medication
- a trial of psychotherapy of adequate frequency and length, with rating scores showing no significant improvement
- no history of psychosis, no current substance use disorder unless in remission, not pregnant or breastfeeding
- a psychiatrist’s prescription, with the infusion given intravenously under monitoring
Those criteria are from the 2022 edition of one insurer’s policy, so ask your own plan in writing for the ones it applies now. Most of this is paperwork you can start now: each medication you have tried with dose, start and stop dates and why it stopped, your therapy dates, your latest rating scores. One person on r/KetamineTherapy describes the other half, a psychiatrist who offered to “write me a letter for insurance on how it helps me”. A letter of medical necessity is easiest to assess when it answers each criterion in turn. The diagnosis wording counts too: the letter should use the policy’s own terms, here unipolar, treatment-resistant major depressive disorder.
Those criteria are an insurer’s short version of a clinical assessment: it checks whether you fit a list. A doctor looks at your whole history and plans treatment around it; ours are two doctors named with their roles and registration.
What to do if your claim is denied
Appeal, and start with the denial letter. Under US federal rules your insurer has to explain in writing why a claim was denied: 15 days for a prior authorisation request, 30 days for care already received, 72 hours for urgent care, according to HealthCare.gov. The reason it gives decides your argument.
For ketamine the reason is usually one of two. “Not medically necessary” is answered with documents showing that you meet the plan’s criteria. “Experimental or investigational” is answered with the published evidence and your treatment history. HealthCare.gov lists both as appealable.
Appeal: the steps and the deadlines
- Read the denial. Keep the Explanation of Benefits and the letter, and ask the plan for the medical policy behind the decision.
- File an internal appeal within 180 days of the denial notice. Use the insurer’s form, or write with your name, claim number and member ID, and ask your own doctor for a letter answering each criterion. Your state’s Consumer Assistance Program can file the appeal for you.
- Wait for the decision: 30 days for treatment you have not had yet, 60 days for treatment already received.
- Request an external review within four months of the final denial. An independent reviewer decides, the insurer must accept the result by law, and a denial on experimental or investigational grounds qualifies. Standard reviews take 45 days, urgent ones 72 hours.
- Keep copies of everything you send, with notes of each call: date, time and who you spoke to.
Filed as soon as the denial arrives, the two decisions take about two to three months: 30 to 60 days internally, up to 45 days for the external review. Add the 180 days to file and the four months to request external review, and the route can run most of a year.
If you get worse while a claim is in the post, do not wait for the decision. Tell the doctor treating you, and use your local emergency number if you are not safe.
Insurance and ketamine in five lines
- Psychiatric visits and therapy fall under behavioral health, an essential health benefit of every Marketplace plan
- Aetna policy 0938, last reviewed December 2025, classes ketamine for depression as experimental by five routes, a payment rule for off-label use
- A 2022 Blue Cross and Blue Shield of Vermont policy covered IV infusions after four failed medications from two classes
- You have 180 days to file an internal appeal and four months to request an external review
- A denial as experimental or investigational can go to external review, and the insurer must accept the result
Manufacturer support programmes
Manufacturer programmes help with brand-name drugs approved for your condition: benefit checks, help with copays and support with prior authorisation. Ketamine for depression sits outside that system. It is a generic anaesthetic made by several companies, and its use for depression is off-label, so there is usually no manufacturer programme to apply to.
What people use in its place:
- A health savings or flexible spending account. IRS Publication 502 lists psychiatric care, therapy received as medical treatment and prescribed medicines as medical expenses, the categories these accounts pay for. People on r/KetamineTherapy ask whether anyone has “used HSA funds for IV KET”; your plan administrator gives the answer for your account.
- Out-of-network reimbursement. If a clinic does not bill your plan, it can give you a superbill, an itemised receipt with the codes, which you submit yourself. The visit and therapy lines are the ones most likely to be paid back.
- A payment plan. Some clinics spread the cost of a course. Ask what happens to the plan if the course changes or stops early.
Before choosing how to pay, work out which route you are paying for, because the paperwork differs: a per-session clinic bill you submit yourself, or one sum for a residential course. If it is the second, you can apply for the programme.
Without insurance: how to add up the full cost of any route
Add up the whole course. A per-session price is the figure most clinics publish, and it is one part of the total. Put each route through the same list:
| What to count | Outpatient infusions, paid per session | Residential programme with medical supervision |
|---|---|---|
| Sessions in the first run | agreed with the clinic, each one billed | inside one sum |
| Sessions after the first run | billed each time | ask whether they are in the sum |
| Psychiatric assessment | often a separate fee | usually part of admission |
| Therapy and integration | sometimes in the clinic’s package, often bought separately, sometimes not at all | usually included |
| Travel | to and from every session, and a ride home after each one | travel once |
| Time off work | each session day, and many people keep the next day free | the time away |
| Accommodation and meals | at home | usually included |
Then ask each provider the same three questions: what the first run costs in total, what happens if it needs extending, and what is left out of the figure. Published per-session figures for the US and London are set out on our page on what a course of infusions and later maintenance sessions cost.
The UK and the EU: how payment works there
In the UK, ketamine for depression is mostly paid for privately. NICE’s depression guideline NG222, published in June 2022, does not include ketamine among its recommendations for treatment-resistant depression, and people describe the result plainly: “Ketamine is not covered by NHS yet, so everything is kind private”, or “NHS but self-pay”.
Private medical insurance fills that gap less often than people hope, because policies are written for new conditions. One large UK insurer lists among its key exclusions pre-existing conditions, chronic conditions that need ongoing treatment, and some outpatient drugs. Depression that has lasted through several treatments tends to fall under the first two, so ask your insurer for the exclusions section of your policy wording.
In the EU, treatment in another member state follows the cross-border healthcare rules: if a treatment is included in your public health insurance at home, you can be reimbursed for the same treatment elsewhere in the EU at the rate your own system pays, sometimes with prior authorisation (European Commission, Your Europe). Where ketamine for depression is not in your home package, there is nothing to reimburse, and people pay for it themselves.
Wherever you live, that makes the comparison one of full cost against full cost. Where ketamine therapy is legal, and in which countries, has its own page. Our programme runs in Malta, about ninety minutes from the airport to the house.
What our single sum covers and how payment works
Our programme is quoted and paid as one sum, not per session, so the comparison with an outpatient course is a comparison of totals. In that sum: three weeks of online preparation, the week in Malta and three weeks of online integration after you return home; a single room, meals and the activities between sessions; a doctor and a nurse with you throughout every ketamine session; one-to-one therapy and group integration. Flights are not included; the airport transfer is arranged. On the outpatient route those same lines are bought one at a time, from different providers, and therapy is often not bought at all. The week in Malta is set out in full.
Payment follows a fixed order. On a 15-minute introductory call the sum is quoted in writing. A medical assessment with Dr Peter Muscat and Dr Christopher Gauci then decides whether the programme suits you, before you pay for the programme. Cancellation terms, including a full refund if you cancel more than 31 days before the first preparation session, are on the page of common questions about the programme.
Find out whether the programme fits you
Tell us what you are dealing with and what you have already tried. Whether it suits you is decided by two doctors at the medical assessment, before you pay for the programme.
No payment and no booking at this step.
Common questions
Does Blue Cross Blue Shield cover ketamine treatment?
It depends on which Blue Cross Blue Shield company insures you, because each is a separate insurer with its own medical policies. A 2022 Vermont policy covered intravenous infusions for treatment-resistant depression under strict criteria and treated other routes as investigational. Ask your plan for its ketamine policy by name, then ask your own doctor to build the prior authorisation request from the criteria written in it.
What insurance companies cover ketamine?
Few cover the ketamine itself for depression, and those that do set conditions. Aetna classes it as experimental for depression; a 2022 Blue Cross and Blue Shield of Vermont policy covered intravenous infusions after documented failure of several treatments. Plans more often pay for the psychiatric visits and therapy around it. Check your own plan’s written policy and keep a note of the codes it names for an infusion and for the visit, because that pairing is what a claim turns on.
Is ketamine treatment covered by Medicaid?
Medicaid is run by each state, and each state sets its own covered services and medical policies, so the answer differs from state to state. Ask your state plan for its written policy on ketamine for depression, and check the psychiatric visits and therapy separately from the session itself. What a course costs without cover is set out on our page on infusion and maintenance costs.
How to get ketamine therapy covered by insurance?
Get the plan’s written ketamine policy, ask your doctor for a prior authorisation request that answers each of its criteria, and attach your treatment history and rating scores. If it is refused, file an internal appeal within 180 days and, if needed, an external review within four months. The medical assessment with our doctors can run while the claim does.
Start by getting your plan’s written policy on ketamine by name, and ask which lines of a session it pays: the psychiatric visits and the therapy are the ones most often covered, the ketamine itself usually is not. Collect what any policy will ask for anyway: every medication you have tried with its dose and dates, your therapy dates, your latest rating scores. Hand that to the doctor who would prescribe, so the request answers the policy’s own criteria rather than describing your case in general. If it comes back refused, read the letter for the stated reason, file the internal appeal within 180 days and ask for external review within four months. If you end up paying yourself, price the full course rather than one session, and ask each provider in writing what the figure leaves out.